Attrition from HIV treatment after enrollment in a differentiated service delivery model: A cohort analysis of routine care in Zambia.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
07
07
2022
accepted:
07
01
2023
entrez:
14
3
2023
pubmed:
15
3
2023
medline:
17
3
2023
Statut:
epublish
Résumé
Many sub-Saharan Africa countries are scaling up differentiated service delivery (DSD) models for HIV treatment to increase access and remove barriers to care. We assessed factors associated with attrition after DSD model enrollment in Zambia, focusing on patient-level characteristics. We conducted a retrospective record review using electronic medical records (EMR) of adults (≥15 years) initiated on antiretroviral (ART) between 01 January 2018 and 30 November 2021. Attrition was defined as lost to follow-up (LTFU) or died by November 30, 2021. We categorized DSD models into eight groups: fast-track, adherence groups, community pick-up points, home ART delivery, extended facility hours, facility multi-month dispensing (MMD, 4-6-month ART dispensing), frequent refill care (facility 1-2 month dispensing), and conventional care (facility 3 month dispensing, reference group). We used Fine and Gray competing risk regression to assess patient-level factors associated with attrition, stratified by sex and rural/urban setting. Of 547,281 eligible patients, 68% (n = 372,409) enrolled in DSD models, most commonly facility MMD (n = 306,430, 82%), frequent refill care (n = 47,142, 13%), and fast track (n = 14,433, 4%), with <2% enrolled in the other DSD groups. Retention was higher in nearly all DSD models for all dispensing intervals, compared to the reference group, except fast track for the ≤2 month dispensing group. Retention benefits were greatest for patients in the extended clinic hours group and least for fast track dispensing. Although retention in HIV treatment differed by DSD type, dispensing interval, and patient characteristics, nearly all DSD models out-performed conventional care. Understanding the factors that influence the retention of patients in DSD models could provide an important step towards improving DSD implementation.
Sections du résumé
BACKGROUND
Many sub-Saharan Africa countries are scaling up differentiated service delivery (DSD) models for HIV treatment to increase access and remove barriers to care. We assessed factors associated with attrition after DSD model enrollment in Zambia, focusing on patient-level characteristics.
METHODS
We conducted a retrospective record review using electronic medical records (EMR) of adults (≥15 years) initiated on antiretroviral (ART) between 01 January 2018 and 30 November 2021. Attrition was defined as lost to follow-up (LTFU) or died by November 30, 2021. We categorized DSD models into eight groups: fast-track, adherence groups, community pick-up points, home ART delivery, extended facility hours, facility multi-month dispensing (MMD, 4-6-month ART dispensing), frequent refill care (facility 1-2 month dispensing), and conventional care (facility 3 month dispensing, reference group). We used Fine and Gray competing risk regression to assess patient-level factors associated with attrition, stratified by sex and rural/urban setting.
RESULTS
Of 547,281 eligible patients, 68% (n = 372,409) enrolled in DSD models, most commonly facility MMD (n = 306,430, 82%), frequent refill care (n = 47,142, 13%), and fast track (n = 14,433, 4%), with <2% enrolled in the other DSD groups. Retention was higher in nearly all DSD models for all dispensing intervals, compared to the reference group, except fast track for the ≤2 month dispensing group. Retention benefits were greatest for patients in the extended clinic hours group and least for fast track dispensing.
CONCLUSION
Although retention in HIV treatment differed by DSD type, dispensing interval, and patient characteristics, nearly all DSD models out-performed conventional care. Understanding the factors that influence the retention of patients in DSD models could provide an important step towards improving DSD implementation.
Identifiants
pubmed: 36917568
doi: 10.1371/journal.pone.0280748
pii: PONE-D-22-19252
pmc: PMC10013882
doi:
Substances chimiques
Anti-Retroviral Agents
0
Anti-HIV Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0280748Subventions
Organisme : NIMH NIH HHS
ID : F32 MH128120
Pays : United States
Informations de copyright
Copyright: © 2023 Jo et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
BMJ Open. 2019 Sep 6;9(9):e030428
pubmed: 31494616
Trop Med Int Health. 2015 Apr;20(4):430-47
pubmed: 25583302
PLoS Med. 2020 Jul 1;17(7):e1003116
pubmed: 32609756
Curr HIV/AIDS Rep. 2019 Aug;16(4):324-334
pubmed: 31230342
J Acquir Immune Defic Syndr. 2021 Jun 1;87(2):e198-e206
pubmed: 33492018
J Int AIDS Soc. 2021 Oct;24 Suppl 6:e25808
pubmed: 34713620
PLoS Med. 2019 Jul 23;16(7):e1002874
pubmed: 31335865
J Acquir Immune Defic Syndr. 2019 Aug 15;81(5):540-546
pubmed: 31021988
BMC Public Health. 2021 Jun 10;21(1):1110
pubmed: 34112135
J Int AIDS Soc. 2018 Feb;21(2):
pubmed: 29479867
AIDS. 2021 Feb 2;35(2):299-306
pubmed: 33170578
Bone Marrow Transplant. 2007 Aug;40(4):381-7
pubmed: 17563735
Gates Open Res. 2021 Dec 8;5:177
pubmed: 35310814
J Int AIDS Soc. 2020 Nov;23(11):e25640
pubmed: 33247517
PLoS One. 2021 Feb 4;16(2):e0246471
pubmed: 33539424
Lancet Glob Health. 2021 May;9(5):e628-e638
pubmed: 33865471